Look­ing to build in red-hot vi­ral vec­tor space, Ther­mo Fish­er inks $878M deal for Bel­gian man­u­fac­tur­er's 2 plants

Be­tween Covid-19 vac­cines and gene ther­a­pies, the con­tract man­u­fac­tur­ing mar­ket for vi­ral vec­tor tech has grown at a rapid clip. Ther­mo Fish­er Sci­en­tif­ic, al­ready one of the biggest CD­MOs on the block, has now made a move to buoy its EU foot­print in that field.

Ther­mo Fish­er will pay $878 mil­lion to ac­quire Henogen SA, No­vasep’s vi­ral vec­tor man­u­fac­tur­ing busi­ness, which com­pris­es two Bel­gian lo­ca­tions in Sen­effe and Gos­selies that of­fer over 75,000 square feet of clin­i­cal and com­mer­cial man­u­fac­tur­ing ca­pac­i­ty, the Mass­a­chu­setts com­pa­ny said Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.